Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease, sexually transmitted diseases, respiratory infections, epstein barr virus, and other viral pathogens; and products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a high risk of developing diabetes. It also develops, manufactures, and distributes products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research industries. The company sells its products through its direct sales force in the United States; and a network of independent distributors and strategic partners internationally. Its customers include public health facilities, hospitals, and other outreach facilities, as well as clinical and reference laboratories. Trinity Biotech plc was founded in 1992 and is headquartered in Bray, Ireland.
Read More
